| General information | |
| ACovPid: | ACoVP100216 |
| Trivial Name: | RBD-11b |
| Amino Acids Sequence: | YKYRYL |
| Length: | 6 |
| C-Terminal Modification: | None |
| N-Terminal Modification: | None |
| Chemical Modification: | None |
| Peptide Source: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
| Source Description: | From the receptor-binding domain (RBD) of the spike protein of SARS-CoV |
| Against Virus: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
| Inhibition Value Type: | IC90 |
| Inhibitory Effect: | 700 |
| Inhibitory Unit: | µM |
| Target Domain Name: | |
| Assay: | Cell-cell fusion |
| Assay Description: | |
| Anti-CoV activity in vivo: | |
| Reference: | 22265858 |
| Comment: | Furthermore, the peptide was alsotested in an inhibition assay with another corona virus NL63 inLLC-MK2 and CaCo2 cells. NL63 corona virus causes severe coldsin human and uses ACE2 also as a functional receptor.(van derHoek et al., 2004; Wu et al., 2009) Inhibitory effects were observedfor both cell lines at a concentration of 14 mM. For CaCo2 cellsinhibition is also observed at a peptide concentration of 7 mM. |
| 3D structure: | |
| Structure Experiment Verified: | NO |
| Similar Peptides: | ACoVP100514 |